enzastaurin(Eli Lilly and Company)은 Non-small Cell Lung Cancer 표적 치료제로, Recurrent Glioblastoma 영역에서 개발·상용화 중입니다. 작용기전: , pharmacokinetic profile, adverse effects, and clinical trial for darovasertib, and future research directions for treating uveal melanoma. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 16.7% (ClinicalTrials.gov NCT00542919). 차별점: novel underlying mechanism for paclitaxel resistance in TNBC but also provides a new potential combinatorial therapeutic stra.
Non-small Cell Lung Cancer
Recurrent Glioblastoma
Active
novel underlying mechanism for paclitaxel resistance in TNBC but also provides a new potential combinatorial therapeutic stra
, pharmacokinetic profile, adverse effects, and clinical trial for darovasertib, and future research directions for treating uveal melanoma
immune-mediated vascular remodeling that includes thickening of the muscular layer surrounding arteries and arterioles
Microtubule-associated serine/threonine kinase-like (MASTL) regulates mitotic progression and is an attractive target for the devel
biomarker of enzastaurin activity
resistance mechanism derived from imatinib treatment that results in a more invasive behavior
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
enzastaurin(Eli Lilly and Company)은 Non-small Cell Lung Cancer 표적 치료제로, Recurrent Glioblastoma 영역에서 개발·상용화 중입니다. 작용기전: , pharmacokinetic profile, adverse effects, and clinical trial for darovasertib, and future research directions for treating uveal melanoma. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 16.7% (ClinicalTrials.gov NCT00542919). 차별점: novel underlying mechanism for paclitaxel resistance in TNBC but also provides a new potential combinatorial therapeutic stra.
Non-small Cell Lung Cancer
Recurrent Glioblastoma
Active
novel underlying mechanism for paclitaxel resistance in TNBC but also provides a new potential combinatorial therapeutic stra
, pharmacokinetic profile, adverse effects, and clinical trial for darovasertib, and future research directions for treating uveal melanoma
immune-mediated vascular remodeling that includes thickening of the muscular layer surrounding arteries and arterioles
Microtubule-associated serine/threonine kinase-like (MASTL) regulates mitotic progression and is an attractive target for the devel
biomarker of enzastaurin activity
resistance mechanism derived from imatinib treatment that results in a more invasive behavior
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.